Adcytherix Raises $122M Series A

Gene therapy company developing AAV-based treatments for rare genetic diseases with focus on CNS and ocular conditions

Key Highlights

Funding Amount: $122M Series A
Valuation: Undisclosed
Headquarters: Cambridge, MA
Founded: 2023
Employees: 40-80
Total Raised: $122M

About the Funding Round

Adcytherix has successfully closed $122M Series A in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

Foresite Capital
Arch Venture Partners
GV

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Adcytherix achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Adcytherix's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2023 and headquartered in Cambridge, MA, Adcytherix has established itself as an innovative player in the biotech space. With 40-80 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Adcytherix plans to:

Accelerate product development and innovation
Expand into new markets and geographies
Grow the team across engineering, sales, and operations
Strengthen partnerships with key industry players
Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Adcytherix's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.

For more information about Adcytherix, visit their website or contact their press office.

Adcytherix